Merck KGaA
XETRA:MRK

Watchlist Manager
Merck KGaA Logo
Merck KGaA
XETRA:MRK
Watchlist
Price: 141.8 EUR 0.04%
Market Cap: 61.7B EUR
Have any thoughts about
Merck KGaA?
Write Note

Merck KGaA
Income from Continuing Operations

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Merck KGaA
Income from Continuing Operations Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Income from Continuing Operations CAGR 3Y CAGR 5Y CAGR 10Y
Merck KGaA
XETRA:MRK
Income from Continuing Operations
€2.7B
CAGR 3-Years
0%
CAGR 5-Years
19%
CAGR 10-Years
9%
ATAI Life Sciences NV
NASDAQ:ATAI
Income from Continuing Operations
-$40.3m
CAGR 3-Years
27%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Bayer AG
XETRA:BAYN
Income from Continuing Operations
-€876m
CAGR 3-Years
N/A
CAGR 5-Years
10%
CAGR 10-Years
N/A
MPH Health Care AG
XETRA:93M1
Income from Continuing Operations
€29.5m
CAGR 3-Years
N/A
CAGR 5-Years
-4%
CAGR 10-Years
N/A
Dermapharm Holding SE
XETRA:DMP
Income from Continuing Operations
€89.3m
CAGR 3-Years
-18%
CAGR 5-Years
4%
CAGR 10-Years
N/A
PharmaSGP Holding SE
XETRA:PSG
Income from Continuing Operations
€16.4m
CAGR 3-Years
16%
CAGR 5-Years
2%
CAGR 10-Years
N/A
No Stocks Found

Merck KGaA
Glance View

Market Cap
61.7B EUR
Industry
Pharmaceuticals

Merck KGaA, a global science and technology company based in Darmstadt, Germany, has carved out a distinctive niche in the life sciences, healthcare, and high-performance materials sectors. With a rich history tracing back to 1668, it stands as one of the oldest pharmaceutical and chemical companies in the world. Merck KGaA operates in three primary business segments: Healthcare, Life Science, and Performance Materials. The Healthcare division focuses on innovative prescription medicines and therapies, while the Life Science segment provides essential tools and services for research and production in the life sciences. Meanwhile, the Performance Materials branch offers state-of-the-art solutions for electronic applications and displays. This diverse portfolio positions Merck KGaA as a critical player in industries that are fundamental to advancements in health and technology. Investors should note that Merck KGaA has made strategic investments in research and development, committing approximately 15% of its annual revenue to this area, underscoring its dedication to innovation and growth. The company boasts a solid financial position, with a revenue forecast expected to rise steadily, driven by a robust pipeline of patented drugs and growing global demand for biopharmaceuticals. With a focus on sustainability and digital transformation, Merck KGaA is not only prepared to thrive in today’s competitive landscape but is also positioning itself for long-term success. By blending a legacy of scientific excellence with contemporary challenges, Merck KGaA represents an intriguing opportunity for investors seeking to navigate the dynamic health and technology markets.

MRK Intrinsic Value
158.43 EUR
Undervaluation 10%
Intrinsic Value
Price

See Also

What is Merck KGaA's Income from Continuing Operations?
Income from Continuing Operations
2.7B EUR

Based on the financial report for Sep 30, 2024, Merck KGaA's Income from Continuing Operations amounts to 2.7B EUR.

What is Merck KGaA's Income from Continuing Operations growth rate?
Income from Continuing Operations CAGR 10Y
9%

Over the last year, the Income from Continuing Operations growth was -7%.

Back to Top